Physician profile
John A Cece
NPI 1437198553
$3,214.81
in general payments reported to CMS, 2019-2025
27 companies · $104 in 2025
The $104 reported for 2025 was less than what a typical Otolaryngology/Facial Plastic Surgery provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $620 · 2020: $66.45 · 2021: $198 · 2022: $791 · 2023: $593 · 2024: $842 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,539.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $495.76 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $361.94 | 2019-2024 | Dupixent |
| Genzyme Corporation | $354.29 | 2022-2025 | |
| Glaxosmithkline, LLC. | $330.05 | 2019-2025 | Nucala |
| Aerin Medical INC. | $315.57 | 2022-2024 | |
| Allergan, INC. | $206.85 | 2019-2022 | |
| Axogen | $175.56 | 2024 | Axoguard Nerve Connector, Avance Nerve Graft, Axoguard Ha+ Nerve Protector |
| Mentor Worldwide LLC | $145.64 | 2022 | |
| Stryker Corporation | $125.19 | 2019 | |
| Csl Behring | $120.78 | 2022-2024 | Haegarda |
| Kaleo, INC. | $118.71 | 2021-2024 | Auvi-Q |
| Qapel Medical INC | $94.90 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $80.81 | 2021-2024 | Eohilia |
| Alk-Abello, INC | $57.74 | 2019-2023 | Odactra, Ragwitek, Grastek |
| Abbvie INC. | $34.37 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $29.87 | 2019 | |
| Intersect Ent, INC. | $24.40 | 2020 | |
| Travere Therapeutics, INC. | $19.94 | 2019 | |
| Phadia US INC. | $18.76 | 2022 | |
| Boston Scientific Corporation | $15.79 | 2019 | |
| Novo Nordisk INC | $15.50 | 2025 | Rybelsus, Ozempic |
| Aimmune Therapeutics, INC. | $15.47 | 2022 | |
| Hikma Pharmaceuticals USA | $14.93 | 2023 | Ryaltris |
| Grifols USA, LLC | $14.35 | 2022 | |
| Pharming Healthcare, INC. | $12.50 | 2019 | |
| Glenmark Therapeutics INC. | $9.00 | 2019 | |
| Checkpoint Surgical, INC | $6.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cece listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.